Table 2.
Fasting plasma concentrations (mean±SD) of adiponectin, adipsin, and oxidative stress markers oxLDL, TAC and GPX-1 in the three different insulin sensitivity groups: M≤6 (n=14), M=6.1–12 (n=29) and M>12 (n=17)
| Most sensitive (M>12, n=17) |
Intermediate sensitive (M=6.1–12, n=29) |
Least sensitive (M≤6, n=14) |
P value | |
| Adiponectin (µg/mL) | 29.1±6.1 | 30.3±10.6 | 23.9±7.7 | 0.121 |
| Adipsin (ng/mL) | 577.7±165.8 | 630.4±186.6 | 537.4±202.4 | 0.319 |
| oxLDL (U/L) | 65.4±28.6 | 54.1±23.5 | 70.1±25.5 | 0.124 |
| TAC (mM Trolox) | 1.8±0.3 | 1.8±0.2 | 1.9±0.2 | 0.253 |
| GPX-1 (ng/mL) | 5.0±6.0 | 4.2±3.8 | 5.0±4.8 | 0.791 |
| CRP (ng/mL) | 1359.2±1012.6 | 2649.8±1872.9* | 2335.4±1156.6* | 0.027 |
| sRAGE (ng/mL) | 1180.5±695.6 | 1151.9±420.0 | 1314.1±561.0 | 0.654 |
| TNFRSF1B (ng/mL) | 2088.4±417.3 | 2174.0±527.3 | 2050.1±381.2 | 0.702 |
*P<0.05 vs M≤6 by ANOVA.
ANOVA, analysis of variance; CRP, C reactive protein; GPX-1, glutathione peroxidase 1; M value, whole-body glucose disposal rate; oxLDL, oxidized low-density lipoprotein; sRAGE, soluble receptor for advanced glycation end products; TAC, Trolox equivalent total antioxidant capacity; TNFRSF1B, soluble tumor necrosis factor alpha receptor 2.